Tuesday November 24 2009 | Biotechnology feed | All feeds

BioPortfolio's Approved Drugs Database

Hycamtin

Topotecan Hydrochloride

Download PDF containing detailed information. PDF Version

Image Results

Press Releases About Hycamtin:
Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting	26th May, 2009	Ascenta Therapeutics	MALVERN, Pa., May 26 /PRNewswire/ -- Ascenta Therapeutics announced today that eleven presentations or publications on pre-clinical and clinical studies of AT-101, an oral, pan-Bcl-2 inhibitor, in
Small-Cell Lung Cancer Drug Market Will More Than Double to Over $684 Million in 2017	8th April, 2009	Decision Resources	Although Market Growth Will be Robust, Drug Development Has Been Disappointing in Recent Years, According to a New Report from Decision Resources WALTHAM, Mass., April 8 /PRNewswire/ -- Decision
Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer	27th February, 2009	Ascenta Therapeutics	- Data presented today at American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium - MALVERN, Pa., Feb. 27 /PRNewswire/ -- Ascenta Therapeutics announced today positive

This page has been viewed 23 times Browse BioPortfolio's InDepth service - alphabetically: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z or by Most Publications, recently searched for, or most viewed.

Search for Hycamtin across BioPortfolio, or for Hycamtin Research Reports

Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH. Thumbshots from Thumbshots.org

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

BioPortfolio's Approved Drugs Database

Hycamtin

Topotecan Hydrochloride

Image Results

Press Releases About Hycamtin: